Our news
BIC Securities announces the successful completion of another M&A transaction in the Russian pharmaceutical sector, in which BIC Securities acted as an exclusive buy-side advisor to Takeda Pharmaceuticals on acquiring of IP rights for certain OTC and FS products from company Unipharm Inc. (USA)

On September 01, 2017 Takeda Pharmaceuticals (Takeda) (TYO: 4502), a leading pharmaceutical company in Japan and one of the leading companies in Asia and worldwide, completed the acquisition of intellectual property rights for certain OTC and FS products from company Unipharm Inc. (USA), including worldwide rights for Vitrum vitamin brand. 

Vitrum brand is the leader in the Russian multivitamins market. According to IMS Health, retail sales of the brand in Russia in 2016 were more than 3bn RUB or 50m USD. 

By acquisition of Vitrum brand Takeda strengthens its position in the Russian and CIS pharmaceutical market. 

BIC Securities acted as an exclusive financial advisor to Takeda during the entire acquisition process: starting from market analysis and search for acquisition targets until signing asset purchase agreement and execution of all conditions for completion of the assets acquisition transaction, thus, once again confirming its leading position among M&A financial advisors in the pharmaceutical sector in Russia. 

Transaction details are not disclosed.

Return to archive
Our company
Publications and presentations
Our news

Quick search

Copyright © 1999-2023 BIC Securities.
All rights reserved.